Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
has someone the link of todays cc ?
shareholder value ??
Thank you Missling !
Still invested, but disillusioned .
Investor 2014
Do you have a life besides this board ? Family? Hobbies ? 24/7 ! ? !
I know a perfect drug for you, it‘ s called Blarcamesine, no side effects, good sleep, better memory
just back to real life . You will be happy again….
Dr. Marwan Sabbagh, chief scientific advisor of Anavex,
interview 8 days ago see link:
Waiting waiting waiting waiting waiting waiting……….
How long ???????????
Damn !!!!
Linkedin:since october 2022 ???????????????
Senior Vice President Regulatory Affairs
Anavex Life Sciences · VollzeitAnavex Life Sciences · Vollzeit Okt. 2022–Heute · 1 Jahr 2 MonateOkt. 2022–Heute · 1 Jahr 2 Monate New York City Metropolitan Area
ir@anavex.com : let‘s do some noise there, wake up call for board of directors,
FIRE MISSLING
100 % right and Missling is the main culprit
something is fishy here, Missling no telling the whole story? 30mg vs 50mg dosage ?
what a mess!!
song of silence , it is pure torture
Last corporate presentation dated may 23, no information, no communication with shareholders since
then , shareholders, that means owner of Anavex, must be frustated the way they are neglected from
Missling , poor CEO…
we shareholders are the owners of this company , communication between
owners and their CEO is essential , but why the silence, no communication nada..
Missling wake up !!!!!
So what ?? You get on my nerves boy !!
„new rare disease“ what a joke, we have been waiting for years to get to know the „new indication “ but nothing , nada ,
Missling has lost any credibility…
Missling is hiding something, he must know the data by now, not releasing them means data failed,
high selling pressure, bad news leaking ??
holy shit, bleeding, bleeding….
my patience is running out, fire storyteller Missling
Where is georgejj ?!!!
https://mcusercontent.com/60520355e3a9761add0b9d1d9/files/00dd6315-191f-b8b0-814b-5742e4d3f976/CEOi_BBM_Workgroup_AAIC_Presentation_07.18.2023.pdf
Missling and Anavex on boat!!
The Blood-Based Biomarker Workgroup
The Global CEO Initiative on Alzheimer's Disease
If anyone had any doubts....the market has lost complete confidence in AVXL, its pipeline, and especially Missling. I am hanging on but by my fingertips.
Fire Missling
Sorry people, I am so excited….
Yessss we got it ..we are the champions .. Monday share price 60 ??
I know it …. See you tomorrow ,,,WGT
Surprising news tomorrow, AVXL presenting at AAIC late breaking news, reversal of disease in AD in 72 % patients WGT
Who laughs last, laughs best
Sava years behind avxl ! Remi Barbier and Cassava nothing but
hot air. See you one year from today and you will understand
what I told you !
Wow, Lonza , that` s a big deal !¨Market cap 40 billions.
Something ` s brewing for sure !
Chewing this gum for 7 years , taste fading as years go by, patience is a virtue but has his limits, we are all shareholders of a company, the company belongs to us shareholders, Missling needs to understand that we are not a basic science laboratory,
DNA, mRNA analysis , analysis over analysis,precison medicine,
KEM platform etc….all hot air. We need real results! ! !
Damn it!¨ Meet endpoints and.do not change them. Basta ! !
Exactly, I meant this one, the one and only Remi Barbier
A 'disoriented' Pain Therapeutics flips out after FDA rejects appeal on Remoxy
Amber Tong
Senior Editor
Pain Therapeutics has had the last word on its four-time reject Remoxy — and it’s a bitter one.
After a meeting with the FDA, the biotech says, “we believe we are no closer today to product approval than we were over a year ago” thanks to “shambolic regulations” at the agency.
Its stock $PTIE promptly fell 20%, tumbling further into pennystock lowland.
advertisement
advertisement
Remi Barbier
The dispute here centers around how easily Remoxy — an extended release gel formulation of oxycodone — can be abused, at a time the deadly opioid crisis has led to calls for heightened vigilance over approval of new pain drugs.
That concern led an expert panel to vote overwhelmingly against the drug before the FDA handed a formal slapdown.
Contrast that with the solid endorsement AcelRx received for its pain med Dsuvia, which was later approved — triggering vocal criticism from an expert on the committee who accuses the FDA for lacking in transparency.
Pain Therapeutics contended the agency misled the advisory committee with “math errors, material mistakes and misrepresentations,” an allegation that regulators denied in their recent meeting with the company.
Before they go silent about their future plans for the drug, CEO Remi Barbier offered a part-eulogy that’s mostly FDA bashing:
Remoxy remains an odyssey without a homecoming. We had hoped for a fair, neutral and impartial review of the Remoxy data. Instead, we walked out of this meeting feeling a bit disoriented by FDA’s lack of transparency, clarity or helpfulness. It’s a rare occasion when two parties can’t agree on simple math. We can’t work with shambolic regulations. This is not how you win support for innovation.
As previously reported, following a reorganization, the biotech plans to focus its remaining resources on a drug for Alzheimer’s, a disease that has defeated every therapy thrown at it for more than a decade.
AUTHOR
Amber Tong
Cassava is a fraud just like their CEO Remi Barbier
he was part of the AD Anavex trial in Australia
now supposedly on the OLE
(Dr Barrie Pittock)
https://www.theage.com.au/national/victoria/this-is-an-opportunity-to-show-what-we-stand-for-20210419-p57kj1.html
April 20, 2021
THE FORUM
Jobs, growth will follow
As a retired climate scientist, with a Public Service Medal and a share in a Nobel prize, I have long been predicting drastic climate changes in the next few decades if we do not quickly reduce greenhouse gas emissions.
The consequences will be disastrous for Australia and the world, with rising sea levels, more extreme storms and floods and droughts, etc ...
We must act quickly to reduce GHG emissions and plan for disaster relief, and profit from a massive expansion in renewable electricity from solar, wind and tidal power and the generation of hydrogen and ammonia as transportable and exportable fuels. Jobs and growth will come with renewable energy.
It is the urgent future for us all. Renewable energy will provide jobs and growth. Get on with it.
Barrie Pittock, Brighton East
Dr Barrie Pittock still in very good mental health
Since 2018 on Anavex 2-73
Thanks a lot!
couldnˆt find any live webcast link on Anavexˆs homepage .
Could someone post the link?
Thx
No it isn‘t. It‘s a genetic disease , Not epigenetic !!
????????????????
News on HL Pharma website about Anavex has disappeared ..
Strange, very strange.....
Prof. Krogan and the team report that a variety of other FDA-approved drugs also target the sigma receptors. The drugs include progesterone, some drugs used to treat allergies, and the antipsychotic haloperidol.
They write that the most promising drug is an experimental anticancer drug called PB28. They found the drug was 20 times more potent than hydroxychloroquine at deactivating the new coronavirus.
Unlike the two antimalarials, PB28 does not bind to the hERG protein. This means that it may be safer at high doses.
Prof. Krogan told the New York Times that scientists have already begun some animal studies to test whether PB28 lives up to its early promise.
A large, unintentional trial of many of the drugs that Prof. Krogan and his team identified is already underway. Because doctors are already treating many COVID-19 patients with these drugs for unrelated conditions, it will be informative to see whether a pattern emerges in their survival rates.
They write: “Many COVID-19 patients will be on the drugs identified here, treating pre-existing conditions. It may be useful to correlate clinical outcomes with the taking of these drugs, cross-referencing with the networks described here.”